A new synthetic corticoid, fluocinolone acetonide (6α, 9α-difluoro 16α, 17α-isopropylidenedioxy-Δ′-hydrocortisone), has been submitted for study.
This report summarizes the results of double blind studies and the effect of this new drug in the treatment of dermatoses which normally respond to topical steroid therapy.
Fluocinolone acetonide proved to be ineffective on oral administration in the treatment of generalized dermatoses which normally respond to systemic steroid therapy.1 When applied topically in suitable vehicles, the steroid was effective in the treatment of eczematous lesions.1
All preparations used in the double blind studies were received under code label. The 4 creams used contained: (1) no medication as a control, (2) 0.025% fluocinolone acetonide, (3) 0.1% triamcinolone acetonide, and (4) 1.0% hydrocortisone. The fluocinolone acetonide cream and lotion used in the balance of this study contained 0.025% of the active ingredient.The formulae of the lotion vehicles are:
ROBINSON HM. Fluocinolone Acetonide. Arch Dermatol. 1961;83(1):149–151. doi:10.1001/archderm.1961.01580070155019
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: